Our study allows a better understanding of the clinical relevance of using PRMT2 as a novel marker of inflammation, thus helping in the prediction of the patient response to anti-inflammatory drugs in the treatment of AML. This evidence concerns the gene PRMT2 and acute myeloid leukemia.